Isomorphic Labs raises $5 billion to push its AI-designed drugs toward trials
Greenoaks and Sequoia co-led the Series C, with a16z joining and Alphabet investing again. Isomorphic says its AI drug-design engine is producing positive preclinical results and setting up its first clinical trials.
A $5 billion round, six months after $2.1 billion, and the company is still describing a human trial as a step it has not taken. Investors are buying the platform story. The clinic is what would start grading it.
On Tuesday, Nov. 17, London-based Isomorphic Labs announced a $5 billion Series C. The company called the round oversubscribed, which means investors offered more money than the company took. Greenoaks and Sequoia Capital co-led. Andreessen Horowitz and other new investors joined, and Alphabet invested again, which the company calls a continued significant investment. Every existing investor came back: Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund. The round size, the co-leads, and that list are Isomorphic's, in its press release.
It follows a $2.1 billion Series B in May, six months ago. TechCrunch and The Next Web both report that May round. The company did not disclose a valuation, the price the new round puts on the whole company. Bloomberg had reported this month that the round would value Isomorphic at about $50 billion. The Next Web attributes that figure to Bloomberg. TechCrunch, also citing Bloomberg, says the lab was looking to raise at a $50 billion valuation. That number is a report. Isomorphic has not published it.
TechCrunch describes Isomorphic as spun out of Google DeepMind in 2021. The company says it was founded that year to design medicines with AI, and The Next Web says it was started to build on AlphaFold. AlphaFold is the DeepMind model that predicts the shape of a protein from its genetic sequence. Hassabis and John Jumper shared the 2024 Nobel Prize in Chemistry for that work. The drug-design engine is called IsoDDE. Pharma partners include Eli Lilly, Novartis, and Johnson & Johnson. The spin-out line and the partner names are TechCrunch's. The engine's name is in the company release and in The Next Web.
Where the drugs stand. Isomorphic says it has positive preclinical results, meaning results from lab and animal work, not from people, in its own cancer and immunology programs and with partners, and that this is "setting the stage for clinical entry." Clinical entry means a human trial. The company has not announced that an Isomorphic drug is in one. In January, Hassabis said he expected the first trials by the end of 2026. The Next Web reports he would not give Bloomberg an updated target, and that he said the company would have more to announce in 2027. Those January and 2027 lines are The Next Web's account of what he told Bloomberg.
The money, as the release describes it, goes to maturing IsoDDE, pushing into new biology and more kinds of drugs, building a partner ecosystem, the infrastructure for what it calls AI-led bioengineering, and the capacity to run clinical development. Hassabis said in the release: "This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients." He told Bloomberg, as The Next Web quotes him: "What we're trying to build is a platform to do hundreds of drugs a year." Neil Mehta, founder of Greenoaks, called drug development "an optimization challenge of almost infinite scale."
The picture is Demis Hassabis on a stage at the World Economic Forum in Davos in January 2025, in a gray suit and blue glasses. Gabriel Lado took it for the World Economic Forum. It is a file photo from that meeting, not a picture from Tuesday's funding announcement.
In plain terms, Hassabis's drug company raised $5 billion, six months after raising $2.1 billion, and it still has not said a drug of its own is in a human trial. It says the lab results are good and that trials are the next stage. It did not say what the company is worth. A Bloomberg report put the round near $50 billion. That figure is the report's.
RELATED
Sources
- Isomorphic Labs
prnewswire.com
- Isomorphic Labs blog
isomorphiclabs.com
- TechCrunch
techcrunch.com
- The Next Web
thenextweb.com




















